| 000 | 01701 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516035500.0 | ||
| 264 | 0 | _c20111206 | |
| 008 | 201112s 0 0 eng d | ||
| 022 | _a1471-2431 | ||
| 024 | 7 |
_a10.1186/1471-2431-11-31 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWiegering, Verena | |
| 245 | 0 | 0 |
_aVaricella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis. _h[electronic resource] |
| 260 |
_bBMC pediatrics _cMay 2011 |
||
| 300 |
_a31 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcyclovir _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aChickenpox _xdiagnosis |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCidofovir |
| 650 | 0 | 4 |
_aCytosine _xanalogs & derivatives |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHerpes Zoster _xdiagnosis |
| 650 | 0 | 4 |
_aHerpesvirus 3, Human _xdrug effects |
| 650 | 0 | 4 |
_aHospitalization _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunocompromised Host _xdrug effects |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOrganophosphonates _xtherapeutic use |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 700 | 1 | _aSchick, Judith | |
| 700 | 1 | _aBeer, Meinrad | |
| 700 | 1 | _aWeissbrich, Benedikt | |
| 700 | 1 | _aGattenlöhner, Stefan | |
| 700 | 1 | _aGirschick, Hermann J | |
| 700 | 1 | _aLiese, Johannes | |
| 700 | 1 | _aSchlegel, Paul G | |
| 700 | 1 | _aEyrich, Matthias | |
| 773 | 0 |
_tBMC pediatrics _gvol. 11 _gp. 31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2431-11-31 _zAvailable from publisher's website |
| 999 |
_c20831894 _d20831894 |
||